GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial ...

The company's vaccine consists of an mRNA sequence encoding a stabilized prefusion F glycoprotein.

"EC approves GSK’s RSV vaccine for adults aged 50-59 years" was originally created and published by Pharmaceutical Technology ...

It's been more than a year since the Food and Drug Administration approved the first vaccine to treat RSV. Since then, newly ...

The study conducted by researchers at the University of Michigan and the U.S. Centers for Disease Control and Prevention and published in the journal Vaccine, evaluated newly approved RSV vaccines: ...

These vaccines are now available to adults 60 and older. In terms of dosage, the CDC recommends a single dose for individuals over 75.

Sanofi said on Monday the U.S. Food and Drug Administration has approved a manufacturing line for its and partner AstraZeneca ...

With the stock now more than cut in half from its 52-week high, the company recently laid out a plan for its business at its ...

240452 in CMAJ (Canadian Medical Association Journal). RSV infections cause major illness, especially in infants and older adults, and rates of infection increase with age. There are now vaccines ...

Focuses on ten product approvals through 2027Expects to submit next-generation COVID vaccine for approval in 2024Expects to submit flu/COVID ...

Delta Air Lines said in an update on Thursday that capacity across the industry was also “moderating” and that its revenue ...

Moderna plans to cut $1.1bn in costs by 2027, pausing and scrapping several R&D programs. See why I think further downside ...